Species Difference in Nisoldipine Oxidation Activity in the Small Intestine

Drug Metabolism and Pharmacokinetics

Volumn 17, Issue 5, 2002, Pages 427-436

  Komura, Hiroshi ^a   Yasuda, Motoko ^a   Yoshida, Nagahiro H ^a   Sugiyama, Yuichi ^b  

^a Research Center Kyoto   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

CYP3A; human; intestinal metabolism; monkey; nisoldipine; species difference

Indexed keywords

EID: 85015584860     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.17.427     Document Type: Article

References (41)

1. Wacher, V. J., Silverman, J. A., Zhang, Y. and Benet, L. Z.: Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomi-metics. J. Pharm. Sci., 87: 1322-1330 (1998).
2. Thummel, K. E., O'Shea, D., Paine, M. F., Shen, D. D., Kunze, K. L., Perkins, J. D. and Wilkinson, G. R.: Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin. Pharmacol. Ther., 59: 491-502 (1996).
3. Paine, M. F., Shen, D. D., Kunze, K. L., Perkins, J. D., Marsh, C. L., McVicar, J. P., Barr, D. M., Gillies, B. S. and Thummel, K. E.: First-pass metabolism of midazolam by the human intestine. Clin. Pharmacol. Ther., 60: 14-24 (1996).
4. Bailey, D. G., Malcolm, J., Arnold, O. and Spence, J. D.: Grapefruit juice-drug interactions. Br. J. Clin. Pharmacol., 46: 101-110 (1998).
5. Takanaga, H., Ohnishi, A., Matsuo, H., Murakami, H., Sata, H., Kuroda, K., Urae, A., Higuchi, S. and Sawada, Y.: Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model. Br. J. Clin. Pharmacol., 49: 49-58 (2000).
6. Iwatsubo, T., Hirota, N., Ooie, T., Suzuki, H., Shimada, N., Chiba, K., Ishizaki, T., Green, C. E., Tyson, C. A. and Sugiyama, Y.: Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol. Ther., 73: 147-171 (1997).
7. Chiba, M., Hensleigh, M. and Lin, J. H.: Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Biochem. Pharmacol., 53: 1187-1195 (1997).
8. Iatsimirskaia, E., Tulebaev, S., Storozhuk, E., utkin, I., Smith, D., Gerber, N. and Koudriakova, T.: Metabolism of rifabutin in human enterocyte and liver microsomes: Kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents. Clin. Pharmacol. Ther., 61: 554-562 (1997).
9. Flinois, J.-P., Chabin, M., Egros, F., Dufour, A., De Waziers, I., Mas-Chamberlin, C. and Beaune, P. H.: Metabolism rate of oxodipine in rats and humans: Comparison of in vivo and in vitro data. J. Pharmacol. Exp. Ther., 261: 381-386 (1992).
10. Lampen, A., Christians, U., Guengerich, F. P., Watkins, P. B., Kolars, J. C., Bader, A., Gonschior, A.-K., Dralle, H., Hackbarth, I. and Sewing, K.-F.: Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab. Dispos., 23: 1315-1324 (1995).
11. Lampen, A., Christians, U., Bader, A., Hackbarth, I. and Sewing, K.-F.: Drug interactions and interindividual variability of ciclosporin metabolism in the small intestine. Pharmacology, 52: 159-168 (1996).
12. Jacobsen, W., Kirchner, G., Hallensleben, K., Mancinelli, L., Deters, M., Hackbarth, I., Baner, K., Benet, L. Z., Sewing, K.-F. and Christians, U.: Small intestinal metabolism of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor lovastatin and comparison with pravastatin. J. Pharmacol. Exp. Ther., 291: 131-139 (1999).
13. Raeissi, S. D., Guo, Z., Dobson, G. L., Artursson, P. and Hidalgo, I. J.: Comparison of CYP3A activities in a subclone of Caco-2 cells (TC-7) and human intestine. Pharmacol. Res., 14: 1019-1025 (1997).
14. Lin, J. H., Chiba, M. and Baillie, T. A.: Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol. Rev., 51: 135-157 (1999).
15. Floren, L. C., Bekersky, I., Benet, L. Z., Mekki, Q., Dressler, D., Lee, J. W., Roberts, J. P. and Hebert, M. F.: Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin. Pharmacol. Ther., 62: 41-49 (1997).
16. Fromm, M. F., Busse, D., Kroemer, H. K. and Eichelbaum, M.: Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology, 24: 796-801 (1996).
17. Wacher, V. J., Wu, C.-Y. and Benet, L. Z.: Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinogen., 13: 129-134 (1995).
18. Benet, L. Z., Wu, C.-Y., Hebert, M. F. and Wacher, V. J.: Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery. J. Control. Release, 39: 139-143 (1996).
19. Thummel, K. E., Kinze, K. L. and Shen, D. D.: Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv. Drug Del. Rev., 27: 99-127 (1997).
20. Humphery, M. J.: Pharmacokinetic studies in the selection of new drugs-a case history on dihydropyridine calcium channel blockers. In Kato, R., Estabrook, R. W. and Cayen, M. N. (ed.): Xenobiotic Metabolism and Disposition, New York, Taylor & Francis, 1989, pp. 245-253.
21. Scherling, D., Karl, W., Ahr, G., Ahr, H. J. and Wehinger, E.: Pharmacokinetics of nisoldipine III. Biotransformation of nisoldipine in rat, dog, monkey, and man. Arzneimittelforchung, 38: 1105-1110 (1988).
22. Heinig, R.: Clinical pharmacokinetics of nisoldipine coat-core. Clin. Pharmacokinet., 35: 191-208 (1998).
23. Regardh, C. G., Baarnhielm, C., Edgar, B. and Hoffmann, K.-J.: Pharmacokinetics and biotransformation of 1,4-dihydropyridine calcium antagonists. In Gibson, G. G. (ed.): Progress in Drug Metabolism, New York, Taylar & Francis, 12, 1990, pp. 41-86.
24. Paine, M. F., Khalighi, M., Fisher, J. M., Shen, D. D., Kunze, K. L., Marsh, C. L., Perkins, J. D. and Thummel, K. E.: Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J. Pharmacol. Exp. Ther., 283: 1552-1562 (1997).
25. Bradford, M. M.: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72: 248-254 (1976).
26. Yamaoka, K., Tanigawara, Y., Nakagawa, T. and Uno, T.: A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharmacobiodyn., 4: 879-885 (1981).
27. Kaminsky, L. S. and Fasco, M. J.: Small intestinal cytochromes P450. Crit. Rev. Toxicol., 21: 407-422 (1992).
28. Lehrmann, C., Ullrich, V. and Rummel, W.: Phenobarbital inducible drug monooxygenase activity in the small intestine of mice. Arch. Pharmacol., 276: 87-98 (1973).
29. Hall, S. D., Thummel, K. E., Watkins, P. B., Lown, K. S., Benet, L. Z., Paine, M. F., Mayo, R. R., Turgeon, D. K., Bailey, D. G., Fontana, R. J. and Wrighton, S. A.: Molecular and physical mechanisms of first-pass extraction. Drug Metab. Dispos., 27: 161-166 (1999).
30. Lin, Y. S., Dowling, A. L. S., Quigley, S. D., Farin, F. M., Zhang, J., Lamba, J., Schuetz, E. G. and Thummel, K. E.: Co-Regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol. Pharmacol., 62: 162-172 (2002).
31. Lown, K. S., Ghosh, M. and Watkins, P. B.: Sequences of intestinal and hepatic cytochrome P450 3A4 cDNAs are identical. Drug Metab. Dispos., 26: 185-187 (1998).
32. Niwa, T., Tokuma, Y., Nakagawa, K. and Noguchi, H.: Stereoselective oxidation of nilvaldipine, a new dihydropyridine calcium antagonist, in rat and dog liver. Drug Metab. Dispos., 17: 64-68 (1989).
33. Baarnhielm, C., Dahlback, H. and Skanberg, I.: In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog, and man. Acta. Pharmacol. Toxicol., 59: 113-122 (1986).
34. Zhang, Q.-Y., Wikoff, J., Dunbar, D. and Kaminsky, L.: Characterization of rat small intestinal cytochrome P450 composition and inducibility. Drug Metab. Dispos., 24: 322-328 (1996).
35. Ohishi, N., Imaoka, S. and Funai, Y.: Changes in content of P450 isozymes in hepatic and renal microsomes of male rat treated with cis-diamminedichloroplatinum. Xenobiotica, 24: 873-880 (1994).
36. Guengerich, F. P., Martin, M. V., Beaune, P. H., Kremers, P., Wolff, T. and Waxman, D. J.: Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem., 261: 5051-5060 (1986).
37. Guengerich, F. P., Peterson, L. A. and Bocker, R. H.: Cytochrome P450-catalyzed hydroxylation and carboxylic acid ester cleavage of Hantzsch pyridine esters. J. Biol. Chem., 263: 8176-8183 (1988).
38. Ahr, H. J., Pleiss, U., Scherling, D. and Siefert, H. M.: Gut wall metabolism of nifedipine: Evidence for the relevant contribution to first-pass effect in dogs. The 12th European Workshop on Drug Metabolism, Basel, Switzerland, September (1990).
39. Niwa, T., Kaneko, H., Naritomi, Y., Togawa, A., Shiraga, T., Iwasaki, K., Tozuka, Z. and Hata, T.: Species and sex differences of testosterone and nifedipine oxidation in liver microsomes of rat, dog and monkey. Xenobiotica, 25: 1041-1049 (1995).
40. Komori, M., Kikuchi, O., Sakuma, T., Funaki, J., Kitada, M. and Kamataki, T.: Molecular cloning of monkey liver cytochrome P-450 cDNAs: Similarity of the primary sequences to human cytochromes P450. Biochim. Biophys. Acta., 1171: 141-146 (1992).
41. Prueksaritanont, T., Gorham, L. M., Hochman, J. H., Tran, L. O. and Vyas, K. P.: Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells. Drug Metab. Dispos., 24: 634-642 (1996).